Propylene Glycol-Free Melphalan Hydrochloride (Evomela) in AL Amyloidosis Patients | oneAMYLOIDOSISvoice
recruiting

Propylene Glycol-Free Melphalan Hydrochloride (Evomela) in AL Amyloidosis Patients

key information

study id #: NCT02994784

condition: Amyloidosis; Systemic

status: Recruiting

purpose:

This is a single arm, open label study designed to evaluate the safety and efficacy of propylene glycol-free melphalan hydrochloride in patients with AL amyloidosis. Treatment will be comprised of propylene glycol-free melphalan hydrochloride administered intravenously at a dose of 70-100 mg/m2/day on Days -3 and -2 as conditioning prior to autologous stem cell transplantation.

intervention: Propylene Glycol-Free Melphalan Hydrochloride

results: https://clinicaltrials.gov/ct2/show/results/NCT02994784

last updated: September 17, 2021

To improve your experience on this site, we use cookies. This includes cookies essential for the basic functioning of our website, cookies for analytics purposes, and cookies enabling us to personalize site content. By clicking on 'Accept' or any content on this site, you agree that cookies can be placed. You may adjust your browser's cookie settings to suit your preferences.
More information

The cookie settings on this website are set to "allow cookies" to give you the best browsing experience possible. If you continue to use this website without changing your cookie settings or you click "Accept" below then you are consenting to this.

Close